Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.
In vitro mechanistic study of a small molecule binding to mutant p53 domains, with no cell-based or clinical data, raising a question about therapeutic potential rather than demonstrating it.
In vitro CRISPR-engineered model system in cord blood HSPCs demonstrating differential effects of TP53 allelic states on colony formation and chromosomal instability, but lacking clinical outcome data or in vivo validation.
This is a journal commentary synthesizing two concurrent primary studies; it raises mechanistic questions about ATR's role in EMT and metastasis but does not itself present original empirical data or a definitive clinical trial result.
Early-phase cell line study profiling molecular responses to kinase inhibitors; identifies potential vulnerabilities but lacks human efficacy data, animal validation, or clinical endpoints needed to guide practice.
This literature review identifies potential mechanisms and conflicting observations about GnRH effects on lungs but does not present original empirical evidence, controlled comparisons, or definitive conclusions—only raising questions for future research.
Mechanistic study in cell lines and xenografts identifying a regulatory pathway; no clinical trial data, and findings require confirmation in human subjects.
In vitro proof-of-concept study demonstrating selective promoter activity in HPV-positive cervical cancer cell lines; no animal or human data, therapeutic efficacy not evaluated.